Comparative Pharmacology
Head-to-head clinical analysis: DARVOCET N 100 versus OXAYDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVOCET N 100 versus OXAYDO.
DARVOCET-N 100 vs OXAYDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and providing analgesia.
Oxycodone is a full opioid agonist with relative selectivity for mu-opioid receptors, although it can bind to kappa-opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone.
Darvocet-N 100 contains propoxyphene napsylate 100 mg and acetaminophen 650 mg. For moderate to moderately severe pain, the typical adult dose is 1 tablet orally every 4 hours as needed. Maximum: 6 tablets per day (600 mg propoxyphene napsylate, 3900 mg acetaminophen).
Oral, 5-10 mg every 4-6 hours as needed for pain; maximum 60 mg per day.
None Documented
None Documented
Propoxyphene: 6-12 hours (prolonged in elderly and hepatic impairment); norpropoxyphene metabolite: 30-36 hours. Acetaminophen: 1.5-3 hours.
Terminal elimination half-life is 3.5-5.5 hours for immediate-release oxycodone; clinically dose every 4-6 hours for sustained analgesia.
Propoxyphene: primarily hepatic metabolism to norpropoxyphene, renal excretion of metabolites (20-25% unchanged propoxyphene). Acetaminophen: renal excretion of glucuronide and sulfate conjugates (90-95% total), 2-4% unchanged.
Primarily renal as unchanged drug and metabolites; ~90% excreted in urine (approx 10% unchanged oxycodone, rest as noroxycodone and oxymorphone conjugates) and <10% in feces via biliary elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic